Protection assessments indicated that gastrointestinal adverse situations, mainly nausea and diarrhea, have been dose-dependent but generally mild and transient. These results founded the therapeutic window and knowledgeable dose assortment for subsequent Period 3 trials.Renal safety continues to be similarly reassuring. Throughout Section 1–thre